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Abstract
Background—The hospital environment is important in the transmission of Clostridium 
difficile, with C. difficile frequently contaminating environmental surfaces. Our objective was to 
evaluate the association between hospital room square footage and acquisition of nosocomial C. 
difficile infection (CDI).
Methods—A case-control study was conducted at a university hospital during the calendar year 
of 2011. Case patients were adult inpatients with nosocomial CDI. Control patients were 
hospitalized patients without CDI, and were randomly selected and matched to cases in a 2:1 ratio 
based on hospital length of stay in 3-day strata. A multivariate model was developed using 
conditional logistic regression to evaluate risk factors for nosocomial CDI.
Results—A total of 75 case patients and 150 control patients were included. On multivariate 
analyses, greater square footage of the hospital room was associated with a significantly increased 
risk of acquiring CDI (odds ratio [OR] for every 50 ft2, 3.00; 95% confidence interval [CI], 
1.75-5.16; P<0.001). Other factors associated with an increased risk of CDI were location in a 
single room (OR, 3.43; 95% CI, 1.31-9.05; P=0.01), malignancy (OR, 4.56; 95% CI, 1.82-11.4; 
P=0.001), and receipt of cefepime (OR, 2.48; 95% CI, 1.06-5.82; P=0.04) or immunosuppressants 
(OR, 6.90; CI, 2.07-23.0; P=0.002) within the previous 30 days.
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Conclusions—Greater room square footage increased the risk of acquisition of CDI in the 
hospital setting, likely due to increased environmental contamination and/or difficulty in effective 
disinfection. Future studies are needed to determine feasible and effective cleaning protocols 
based on patient and room characteristics.
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INTRODUCTION
Clostridium difficile has rapidly emerged as the leading cause of healthcare-associated 
infectious diarrhea [1, 2]. Infections due to C. difficile are associated with significant 
morbidity and mortality, with clinical presentation ranging from diarrhea to 
pseudomembranous colitis, toxic megacolon, and sepsis [3]. Established risk factors for C. 
difficile infection (CDI) include advanced age [4, 5], prolonged hospital stay [6], 
immunosuppression [7, 8], and exposure to various classes of antibiotics [9, 10].
Multiple studies have demonstrated that C. difficile is capable of frequently contaminating 
the hospital environment, including patient skin sites, hands of healthcare workers, and 
hospital room surfaces [11-15] such that transmission can occur directly via healthcare 
worker-patient contact or indirectly from contaminated surfaces [16, 17]. In addition, C. 
difficile is capable of forming endospores that are resistant to many sterilization and 
disinfection measures including heat, 70% ethanol (i.e., the main component in hand 
sanitizers), and quaternary ammonium compounds, thus facilitating its persistence on 
environmental surfaces [15, 18]. Along these lines, studies have shown that room 
assignment is important in the acquisition of C. difficile, with patients placed in a room with 
a previous occupant with CDI having a significantly increased risk of CDI [19, 20].
While previous studies support an important role for the hospital environment in the 
acquisition of nosocomial CDI, there have been no studies to date assessing the association 
between hospital room size and risk of CDI. The objective of our study was to evaluate the 
association between C. difficile infection and hospital room square footage, with the 
hypothesis that a greater square footage would be associated with an increased risk of 
acquiring C. difficile.
METHODS
Study design
A case-control study was performed at the Hospital of the University of Pennsylvania 
(HUP), a 775-bed tertiary care academic medical center. Case patients were defined as those 
with a first episode of nosocomial C. difficile (i.e., positive test result for C. difficile >72 
hours after admission) from January 1, 2011 to December 31, 2011. A CDI case was 
confirmed as an initial episode according to standard surveillance definitions in a patient 
with no prior episode in the preceding 8 weeks [21] and was determined to represent an 
infection as opposed to colonization by case review by an infection preventionist. Testing 
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for C. difficile was performed at the HUP Clinical Microbiology Laboratory, and involved 
glutamate dehydrogenase antigen EIA screening followed by toxin A/B EIA testing to 
confirm positive results.
Study population
The source population for control patients was comprised of patients who were hospitalized 
at HUP in the same calendar year who did not have any positive CDI test results. Control 
patients were randomly selected and matched to case patients in a 2:1 ratio based on “time at 
risk” in 3-day strata. The “time at risk” for case patients was defined as the date of 
admission to the date of the first positive C. difficile test. For control patients, “time at risk” 
was defined as the date of admission to the date of hospital discharge. The primary exposure 
of interest was the square footage of the room (length × width) that the patient had occupied 
at the time of CDI diagnosis.
Patients known to be C. difficile positive from prior admissions (e.g., relapsing or recurrent 
disease) and those who were in the intensive care unit were excluded. Patients were also 
excluded if they had transferred room locations prior to the positive test for cases, or prior to 
discharge for controls. If a patient had more than one positive test for C. difficile during the 
study period, only the first episode was included. The study was approved by the 
institutional review board (IRB) of the University of Pennsylvania.
Data Collection
All cases of C. difficile during calendar year 2011 were ascertained from the University of 
Pennsylvania Health System (UPHS) Department of Healthcare Epidemiology and Infection 
Control. Data on case and control patients were abstracted from Penn Data Store, a 
comprehensive electronic database which includes demographic, laboratory, billing, and 
pharmacy information. Information was collected on demographics (e.g., age, weight), room 
locations within the hospital from admission to discharge, comorbidities (e.g., diabetes, 
malignancy), service of admission (e.g., general medicine, oncology), prior admission to 
UPHS in the previous 90 days, and hospital length of stay. Data was also collected on the 
square footage of the hospital rooms for case and control patients.
Data on medications received in the 30 days prior to the positive test date or discharge for 
case and control patients, respectively, were collected. Medication data included the use of 
antibiotics, proton-pump inhibitors, corticosteroids, and immunosuppressants (i.e. 
azathioprine, cyclosporine, mycophenolate, sirolimus, tacrolimus). Antibiotics were 
classified for the purposes of analysis, as follows: aminoglycosides; macrolides; 
fluoroquinolones; extended-spectrum cephalosporins (i.e. ceftriaxone, ceftazidime, 
cefpodoxime); first-generation cephalosporins (i.e. cefadroxil, cefazolin, cephalexin); 
penicillins (i.e. ampicillin, amoxicillin, amoxicillin-clavulanate, nafcillin); carbapenems; 
piperacillin-tazobactam; cefepime; metronidazole; intravenous vancomycin; clindamycin; 
trimethoprim-sulfamethoxazole; and anti-anaerobic agents.
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Statistical Analysis
Case and control patients were characterized by potential risk factors, including 
demographics, square footage of the patient’s hospital room, comorbidities, and prior 
medication use. Descriptive statistics were conducted to characterize the overall study 
population. Since data were matched, conditional bivariate logistic regression was used 
examine the relationship between each potential risk factor and infection with C. difficile. To 
examine the relationship between square footage while adjusting for other possible risk 
factors, multivariate conditional logistic regression was performed. To limit the number of 
variables tested in a single model, on initial pass, variables from bivariate analyses with P 
values <0.10 were evaluated and considered for inclusion in the final multivariate model. 
Backward stepwise selection was performed for selection of variables in the final 
explanatory model, with results confirmed using likelihood ratio testing. Data are presented 
as odds ratios (OR) with 95% confidence intervals (CI). All analyses were were performed 
using STATA v.12 (StataCorp, College Station, Texas).
RESULTS
Study population
A total of 468 cases of C. difficile occurred during the study period. Of these cases, 103 
(22%) were confirmed to be hospital-acquired infections. After application of inclusion and 
exclusion criteria, there were a total of 75 case patients included in this study, each of which 
were randomly matched to controls in 2:1 ratio (n=150) based on “time at risk.” Among case 
patients, the median length of stay prior to positive C difficile testing was 9 days 
(interquartile range [IQR], 7-15 days).
Among the entire study cohort, the median age of patients was 60 years (IQR, 50-70 years), 
and 117 (52%) were men. Of these 225 patients, 139 (62%) were categorized as “white” in 
regard to racial classification. Notably, there was a high prevalence of overweight/obesity 
(body mass index [BMI] ≥25) (65%) and malignancy (47%) present in the study cohort. 
None of the patients in the study cohort were located in a room where the immediately 
preceding occupant had CDI.
Risk factors for nosocomial CDI
On bivariate analyses (Table 1), there was a significant association between risk of C. 
difficile and non-white race (OR, 0.37; 95% CI, 0.20-0.72; P=0.003), as well as overweight 
or obesity (OR, 2.74; 95% CI, 1.39-5.40; P=0.004). Bivariate analysis also demonstrated a 
significant association between CDI and location in a single room (OR, 3.74; 95% CI, 
1.76-7.96; P=0.001), hospital room square footage (OR, 2.03; 95% CI, 1.40-2.94; P<0.001), 
prior admission to the hospital within the past 90 days (OR, 2.59; 95% CI, 1.04-6.50; 
P=0.04), and malignancy (OR, 2.92; 95% CI, 1.56-5.47; P=0.001).
Regarding medication use, there was a significantly increased risk of CDI with prior receipt 
of clindamycin (OR, 3.50; 95% CI, 1.02-12.0; P=0.046), cefepime (OR, 1.94; 95% CI, 
1.05-3.59; P=0.03), corticosteroids (OR, 2.14; 95% CI, 1.20-3.80; P=0.009), and 
immunosuppressants (OR, 5.70; 95% CI, 2.07-15.7; P=0.001).
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On subsequent multivariate analyses (Table 2), hospital room square footage was an 
independent risk factor for acquisition of nosocomial C. difficile (OR for every 50 ft2, 3.00; 
95% CI, 1.75-5.16; P<0.001). Single room assignment (OR, 3.43; 95% CI, 1.31-9.05; 
P=0.01), malignancy (OR, 4.56; CI, 1.82-11.4; P=0.001), and previous receipt of cefepime 
(OR, 2.48; 95% CI, 1.06-5.82; P=0.04) and immunosuppressants (OR, 6.90; 95% CI, 
2.07-23.0; P=0.002) were also significantly associated with an increased risk for acquiring 
nosocomial C. difficile.
DISCUSSION
In this case-control study, we found that that greater hospital room square footage was a 
significant risk factor for acquisition of nosocomial C. difficile after adjustment for other 
known risk factors. CDI was also significantly associated with single room assignment, 
presence of malignancy, and recent receipt of cefepime.
Previous epidemiologic studies have demonstrated that the hospital environment, including 
room assignment, is critical in the acquisition of nosocomial CDI.[11, 19, 20] However, to 
our knowledge, this is the first study to demonstrate an association between hospital room 
square footage and CDI. Environmental contamination plays an important role in the 
transmission of C. difficile in the hospital setting, with greater intensity of contamination 
increasing transmission risk [22, 23]. It is likely that a larger hospital room allows for more 
contamination of surfaces with C. difficile spores and subsequent increased risk of 
acquisition. In addition, a hospital room with greater square footage is more likely to contain 
a greater number of objects (e.g., medical equipment) that may become contaminated and 
thereby increase risk of transmission to subsequent room occupants. Finally, it is likely that 
a larger room increases the potential for inadequate room cleaning, particularly given the 
high demand for bed turnover in many hospitals.
Given that up to 50% of hospital surfaces are not cleaned appropriately by hospital 
environmental services staff during terminal cleaning [24, 25], this finding has important 
implications for the hospital setting. It is clear that interventions to improve room cleaning, 
including all surfaces in addition to high-risk objects, are needed. Newer modalities (e.g., 
hydrogen peroxide vapor or mist, UV-C light) [26, 27] show significant promise in reducing 
surface contamination with C. difficile in hospital rooms. In addition, organizational factors, 
including education of environmental services staff, bed management, and allocation of time 
and resources for cleaning dependent on different factors (e.g., prior occupant colonized or 
infected with a multidrug-resistant organism, room size), should be the focus of future 
studies.
The results of our study also demonstrated a significant association between malignancy and 
CDI. Patients with malignancies are at an increased risk for acquiring CDI for a number of 
reasons, including prolonged hospitalization, use of broad-spectrum antibiotics, bone 
marrow and peripheral blood stem cell transplantation, and neutropenia [28]. The incidence 
of CDI in cancer patients receiving chemotherapy has been reported to be as high as 7%, 
compared to 1–2% in the general hospitalized population [28]. Patients with malignancy, as 
in our study, frequently receive chemotherapeutic agents, which likely increases the risk of 
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CDI given alterations in bowel flora and depression of the immune system [29]. Along these 
lines, patients who received immunosuppressants in the past 30 days in our study were also 
found to have a significantly increased risk for acquiring C. difficile, including those who 
were recent recipients of solid organ transplants [30].
We also found a significant association between CDI and location in a single room. Single 
rooms are often reserved for patients on contact precautions due to colonization or infection 
with multidrug-resistant organisms. Therefore, location in a single room may be a proxy for 
patients who are at greater risk for hospital-acquired infections such as CDI. In addition, 
while there was no significant difference in median square footage of single versus double 
rooms in our study (P=0.75), patients with malignancy were more likely to be located in 
single rooms (P<0.001). Finally, single rooms are often in the highest demand for new 
hospital admissions, and the requirement to turn over these rooms on a timely basis may 
increase the potential for inadequate cleaning.
In the final multivariable model, cefepime use in the prior 30 days was also shown to 
increase the risk for acquiring nosocomial C. difficile. While a wide variety of antibiotic 
agents and classes have been associated with CDI [9, 10], given its broad-spectrum activity, 
cefepime may be particularly likely to disrupt the endogenous gastrointestinal flora, thereby 
increasing the risk of colonization and infection with C. difficile.
There are potential limitations of our study. Misclassification bias is a concern in case-
control studies. However, the outcome of nosocomial CDI was validated through chart 
review by infection preventionists rather than relying on diagnostic or billing codes. While 
there were no health system changes in regard to room cleaning or isolation precaution 
protocols during the study period, we did not have data on adequacy of room cleaning or 
adherence to contact precautions that may have affected surface contamination with C. 
difficile. Given the retrospective nature of the study, we also did not have data on the 
number of objects (e.g., medical equipment) present in the hospital room. Finally the present 
study was conducted in a single healthcare system, and these results may not be 
generalizable to other institutions.
In conclusion, the results of our study demonstrate that greater hospital room square footage 
is a significant risk factor for nosocomial CDI. This finding highlights the importance of the 
hospital environment in the transmission of CDI, and the need for interventions to improve 
environmental disinfection processes in the hospital setting. Future studies should also focus 
on the role of organizational factors and CDI transmission risk, including bed management 
and allocation of disinfection and environmental services resources based on patient location 
and characteristics.
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Summary: We evaluated risk factors for nosocomial C. difficile infection (CDI), with a 
specific focus on the hospital environment. We found that increased square footage of the 
hospital room was a significant risk factor for CDI.
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Table 1
Bivariate conditional logistic regression of risk factors for nosocomial C. difficile infection 
among hospitalized patients
Variable Cases(n=75)
Controls
(n=150) OR (95% CI) P value
Age, median years (IQR) 60 (51-70) 59 (49-70) ---- 0.66
Female sex 35 (47) 73 (49) 0.93 (0.54-1.56) 0.78
Non-white race 18 (24) 68 (45) 0.37 (0.20-0.72) 0.003
Overweight/Obesityb 59 (79) 88 (59) 2.74 (1.39-5.40) 0.004
Surgical service 20 (27) 49 (33) 0.74 (0.39-1.38) 0.34
Single room 66 (88) 97 (65) 3.74 (1.76-7.96) 0.001
Hospital room square
footage, median (IQR) 191 (191-244) 180 (168-198) 2.03 (1.40-2.94) <0.001
Hospital admission in the
previous 90 days 11 (15) 9 (6) 2.59 (1.04-6.50) 0.04
Comorbidities
Chronic kidney disease 5 (7) 28 (19) 0.31 (0.11-0.84) 0.02
Malignancy 47 (63) 59 (39) 2.92 (1.56-5.47) .001
Pulmonary disease 5 (67) 17 (11) 0.56 (0.20-1.58) 0.27
Cardiac disease 12 (16) 29 (19) 0.79 (0.37-1.67) 0.53
Solid organ or
hematopoietic stem cell
transplant in prior 6
months
3 (4) 9 (6) 0.64 (0.17-2.50) 0.52
Cirrhosis 2 (3) 8 (5) 0.50 (0.10-2.35) 0.38
Cerebrovascular disease 1 (1) 8 (5) 0.22 (0.27-1.87) 0.17
Medicationsc
Cefepime 39 (52) 57 (38) 1.94 (1.05-3.59) 0.03
Clindamycin 7 (9) 4 (3) 3.50 (1.02-12.0) 0.046
First-generation
cephalosporin 9 (12) 36 (24) 0.39 (0.16-0.92) 0.03
Corticosteroids 45 (60) 62 (41) 2.14 (1.20-3.80) 0.009
Immunosuppressants 17 (23) 9 (6) 5.70 (2.07-15.7) 0.001
Abbreviations: OR, odds ratio; CI, confidence interval; IQR, interquartile range.
a
Data are presented as numbers (percentages) except where noted.
b
BMI ≥25.
cOnly variables with P<0.05 are shown.
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Table 2
Multivariate conditional logistic regression of risk ractors for nosocomial C. difficile 
infection among hospitalized patients
Variable OR (95% CI) P value
Square footage (every 50 ft2) 3.00 (1.75-5.16) <0.001
Single room 3.43 (1.31-9.05) 0.01
Malignancy 4.56 (1.82-11.4) 0.001
Cefepimea 2.48 (1.06-5.82) 0.04
Immunosuppressantsa 6.90 (2.07-23.0) 0.002
Abbreviations: OR, odds ratio; CI, confidence interval.
a
Receipt within prior 30 days.
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